Comparison of published biomedical studies shows that a large proportion are irreproducible, causing severe damage to society and creating an image of wasted investments. These observations are of course damaging to the biomedical research field, which is currently full of future promise. Precision medicine and disease prevention are successful, but are progressing slowly due to irreproducible study results. Although standardization is mentioned as a possible solution, it is not always clear how this could decrease or prevent irreproducible results in biomedical studies. In this article more insight is given into what quality, norms, standardization, certification, accreditation and optimized infrastructure can accomplish to reveal causes of irreproducibility and increase reproducibility when collecting biomaterials. CEN and ISO standards for the sample pre-analytical phase are currently being developed with the support of the SPIDIA4P project, and their role in increasing reproducibility in both biomedical research and diagnostics is demonstrated. In particular, it is described how standardized methods and quality assurance documentation can be exploited as tools for: 1) recognition and rejection of ‘not fit for purpose’ samples on the basis of detailed sample metadata, and 2) identification of methods that contribute to irreproducibility which can be adapted or replaced.

Additional Metadata
Persistent URL dx.doi.org/10.1016/j.nbt.2019.06.007, hdl.handle.net/1765/117552
Journal New Biotechnology
Citation
Riegman, P.H.J. (P. H.J.), Becker, K.F. (K. F.), Zatloukal, K, Pazzagli, M, Schröder, U. (U.), & Oelmuller, U. (2019). How standardization of the pre-analytical phase of both research and diagnostic biomaterials can increase reproducibility of biomedical research and diagnostics. New Biotechnology (Vol. 53, pp. 35–40). doi:10.1016/j.nbt.2019.06.007